2020
DOI: 10.1038/s41571-020-0340-z
|View full text |Cite|
|
Sign up to set email alerts
|

Lineage plasticity in cancer: a shared pathway of therapeutic resistance

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

12
292
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 339 publications
(305 citation statements)
references
References 123 publications
12
292
0
1
Order By: Relevance
“…Tumor cell conversion into a different phenotype has been associated with therapeutic resistance [4]. Approximately 20% of advanced prostate cancer patients experience cell plasticity and the acquisition of new phenotypes often associated with loss of androgen receptor signaling [35].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Tumor cell conversion into a different phenotype has been associated with therapeutic resistance [4]. Approximately 20% of advanced prostate cancer patients experience cell plasticity and the acquisition of new phenotypes often associated with loss of androgen receptor signaling [35].…”
Section: Discussionmentioning
confidence: 99%
“…Recent theories postulate that as tumor cells display a high plasticity, therapy exposure and environmental signals can induce phenotype switching towards different phenotypes that are associated with drug resistance, a phenomenon named "lineage plasticity" [3,4]. For instance, in 25% of metastatic prostate carcinoma patients treated with anti-androgen therapy, tumor relapses with morphological features of neuroendocrine carcinoma named neuroendocrine prostate cancer (NEPC) [5,6].…”
Section: Introductionmentioning
confidence: 99%
“…Active genomic research has led to the discovery of driver genes/mutations critical to lung cancer [ 31 ]. Molecularly targeted drugs were developed based on these driver genes, and the prognosis of advanced LUAD has greatly improved due to the emergence of molecularly targeted therapeutic agents [ 32 ]. However, even with these therapeutic agents, it is difficult to eliminate cancer cells from patients.…”
Section: Discussionmentioning
confidence: 99%
“…556 The contributions made by neuroendocrine trans-differentiation to the resistance to TKIbased therapy in EGFR-mutant NSCLC have been excellently presented in a number of recent reviews. 26,521 The mechanism behind re-activation of developmental programs Although somatic and neoplastic stem cells reside at the top of the lineage hierarchy, extensive studies have shown that, under certain conditions, not all carcinoma types strictly conform to the generally accepted unidirectional hierarchical model of CSC. This results in a phenotypic switching whereby non-CSCs acquire characteristics of CSCs, such as self-renewal capacity and a slowcycling state.…”
Section: Transition Between Non-csc and Csc States Definition And Chamentioning
confidence: 99%